Moneycontrol PRO
HomeNewsLupinlaboratories

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to
  • Lupin Q2 Preview: Adjusted profit may decline sharply on subdued revenue, operating performance

    Guidance for launches and traction in the US in the second half of FY21 and update on albuterol market share after its launch in the American market would be key things to watch out for.

  • Lupin Q4 preview: Double-digit decline seen in profit, revenue

    Lupin Q4 preview: Double-digit decline seen in profit, revenue

    Motilal Oswal feels domestic formulation business is expected to drive revenue growth, but US sales may decline 10 percent YoY.

  • Lupin Q3 PAT may dip 16% YoY to Rs. 286.4 cr: Sharekhan

    Lupin Q3 PAT may dip 16% YoY to Rs. 286.4 cr: Sharekhan

    Net Sales are expected to decrease by 0.2 percent Y-o-Y (up 0.5 percent Q-o-Q) to Rs. 3,970 crore, according to Sharekhan.

  • Lupin Q4 PAT may dip 5.1% YoY to Rs. 340.7 cr: KR Choksey

    Lupin Q4 PAT may dip 5.1% YoY to Rs. 340.7 cr: KR Choksey

    Net Sales are expected to decrease by 3 percent Y-o-Y (up 3.5 percent Q-o-Q) to Rs. 4,037.9 crore, according to KR Choksey.

  • Lupin Q2 PAT may dip 38.8% YoY to Rs. 405.3 cr: Kotak

    Lupin Q2 PAT may dip 38.8% YoY to Rs. 405.3 cr: Kotak

    Net Sales are expected to decrease by 5.4 percent Y-o-Y (up 4.8 percent Q-o-Q) to Rs. 4057.2 crore, according to Kotak.

  • Expect margins to improve by 100bps in FY13: Lupin

    Expect margins to improve by 100bps in FY13: Lupin

    In an interview to CNBC-TV18, Lupin Managing Director Kamal K. Sharma analysed the performance of the company in the second quarter.

  • Lupin Labs Dec qtr PAT seen up 36.3% at Rs 197.9cr: Karvy

    Lupin Labs Dec qtr PAT seen up 36.3% at Rs 197.9cr: Karvy

    Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Lupin Laboratories December quarter sales are expected to go up by 18.3% at Rs 1485.3 crore, Year-on-Year, (YoY) basis.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347